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Ab s t r a c t
Endolymphatic sac tumour (ELST) is a primary low-grade, locally invasive adenocarcinoma of the endolymphatic sac, charac-
terized by the proliferation of cuboidal cells forming a papillotubular pattern and colloid-filled cysts. Rare in the general
population, it coincides significantly with the presence of von Hippel-Lindau disease. The natural history, mechanisms under-
lying the early symptoms, anatomical origin of ELST and optimal timing of their treatment are unknown. In this study,
we report a Polish male patient with sporadic ELST (without a family history of VHL disease) along with a review of lit-
erature. The light microscopic and immunohistochemical features as well as clinical presentation were typical of ELST.
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Introduction 
Endolymphatic sac tumour (ELST) is a rare, locally
invasive neuroectodermal neoplasm occurring in the po -
steromedial petrous portion of the temporal bone. It
is presumed to originate from pars rugosa of the endo -
lymphatic sac. Symptoms betokening ELST usually in -
clude hearing loss, tinnitus, vertigo, aural fullness, and
facial nerve dysfunction. Histologically, ELST is char-
acterized by the proliferation of cuboidal cells forming
a papillotubular pattern and occasional colloid-filled
cysts, reminiscent of thyroid papillary carcinoma. The pre -
sence of ELST coincides with von Hippel-Lindau disease
(VHL). It remains to be verified what the natural his-
tory and optimal timing of treatment are.
Case description
An 70-year-old Caucasian male presented with 
a 2-year history of progressive left-sided hearing loss
and six-month history of ipsilateral facial paresis. 
On examination he was deaf in the left ear and had
a complete left facial nerve paralysis. Other symptoms
included: disequilibrium, tinnitus and hypoesthesia 
of the left half of the face. Eight weeks before medi -
cal examination he reported experiencing swallowing
problems. 
Magnetic resonance imaging showed a solid, het-
erogeneous enhancing mass in the petrous portion of
the left temporal bone with severe erosion and dam-
age to the anterior petrous pyramid. The 5th, 7th and
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8th cranial nerves were involved but cerebellar incisure
of dura remained intact.
The patient underwent resection of the tumour by
a retrosigmoid approach. The seventh and eighth cra-
nial nerves and all adjacent dura and bone were re -
moved. A small portion of the tumour was firmly adher-
ent to the petrous bone and could not be re moved
completely. The patient recovered uneventfully.
Six months later, the patient complained of facial
symptoms similar to those reported before surgery along
with swallowing difficulties. Computed tomography
revealed recurrence, but due to poor general condition
he was disqualified for surgery and referred to the radi-
ation therapy unit at the neurological hospital. 
Two years after the operation, he died because of
heart attack.
The patient did not show any evidence of VHL and
his family histories were negative as well.
Histopathology
Microscopically, the tumour consisted of complex
papillary glandular structures present in the fibrous stro-
ma. The papillae were covered by a single or double
layer of cuboidal cells, partially flattened. The papillary
stroma was richly vascularized. There was a slight nu -
clear polymorphism of the tumour cells, and only two
mitotic figures were counted in the microscopic sli des.
The growth pattern was invasive, with destruction of
the bone.
Formalin-fixed, paraffin-embedded tissues from 
the ELST were routinely processed and stained with he -
ma toxylin and eosin. For immunohistochemical stud-
ies, 4 µm-thick sections were cut from paraffin blocks,
mounted on slides coated with 3-aminopropyltrietho -
xy-silane (Sigma, St. Louis, USA), deparaffinized in
xylene, and rehydrated in descending grades (100-70%)
of ethanol. Sections were then subjected to heat-in -
duced epitope retrieval in a 0.01 mol/l concentration
of citrate buffer (pH 6.0) in the microwave oven for 
40 min. Endogenous peroxidase was blocked by a 5 min.
treatment with 3% hydrogen peroxidase in absolute
methanol.
The slides were incubated for 60 min. at room tem-
perature with the primary antibodies: S-100 protein
(Dako, cat. no Z0311, at dilution 1 : 300), EMA (Dako,
cat. no M0613, at dilution 1 : 100), CK (Dako, cat. no
M0821, at dilution 1 : 100), NSE (Dako, cat. no M0873,
at dilution 1 : 200) GFAP (Dako, cat. no Z0334, at dilu-
tion 1 : 600), CK7 (Dako, cat. no M7018, at dilution 1 : 50),
CK20 (Dako, cat. no M7019, at dilution 1 : 50), trans -
thyretin (Dako, cat. no A0002, at dilution 1 : 200), Kir 7.1
(Abcam, cat. no ab81117, at dilution 1 : 300), and Ki-67
(DAKO, cat. no M7240, at dilution 1 : 100). The bound
antibodies were visualized with techniques according
to manufacturers’ schemes. The slides were counter-
stained with Mayer’s hematoxylin.
Immunohistochemical studies displayed an expres-
sion of S-100 protein, EMA, CK and NSE in the tu mour
cells (see Fig. 1). Only some epithelial cells express CK7.
The cells did not express CK20, transthyretin, GFAP or
Kir 7.1. Proliferation index (Ki-67) was at the range of 5%.
Discussion
Endolymphatic sac tumour as a distinct entity was
described in the 1980s [14,15]. Since that time a total
of less than 100 cases have been reported. They usu-
ally present in the third and fourth decades of life; some
studies report a female predominance [13,22]. The occur-
rence of ELST in paediatric patients has also been des -
cribed [2,9,11].
Very rarely ELST might occur sporadically as well 
as hereditary connected to von Hippel-Lindau disease
[30]. This connection was observed in 1992 for the first
time and then confirmed by molecular genetic analy-
ses of the VHL gene (3p25) which acts as tumour sup-
pressor [20,21,28]. The association with VHL disease
is estimated for 11-16% [8,24]. 30% of patients with VHL
syndrome and endolymphatic sac tumours have bilat-
eral disease [24]. When ELSTs occur bilaterally, von Hip-
pel-Lindau syndrome is always present [31], and in most
reports, ELST may be a manifestation of VHL syndrome
[24,29,30,34].
The ectodermal endolymphatic sac is a part of the
membranous labyrinth and plays an important role in
regulating inner ear endolymph [1]. ELSTs are thought
to arise from the pars rugosa of the endolymphatic 
sac (adjacent to the endolymphatic duct, partially in -
tra osseous), and therefore invade petrous temporal
bone as well as dura-mater of the posterior fossa
[15,23,25]. Also, they are reported to arise from the dis-
tal smooth portion of the endolymphatic sac and extend
predominantly from the inner ear to the region of the
jugular foramen, sparing the petrous pyramid. The facial
nerve is often involved and invaded by the tumour.
Tumour may also be found adherent to the ascending
vertical portion of the petrous carotid artery [10].
The slow pattern of growth correlates with the insid-
ious onset of hearing loss, vertigo, and facial nerve pare-
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sis, although onset of sudden unilateral deafness has
been described secondary to ELST [12]. The average
duration of symptoms varies from 9.3 to 10.6 years [17].
Radiologically (in CT and MR) a heterogeneous mass
located and eroding the structures of the temporal 
bone is seen, centred in the sigmoid sinus, and grow-
ing towards the cerebello-pontine angle [4]. They appear
hyper-intense on both T1- and T2-weighted MR ima -
ges and show heterogeneous contrast enhancement
[11]. Calcifications are seen in the tumour (spiculae),
Fig. 1. Endolymphatic sac tumour microscopic patterns: (A) papillary (B) cystic and (C) solid with clear cells
(haematoxylin-eosin). The tumour cells showed positivity with cytokeratin (D), NSE (E) and S-100 (F). All pho-
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there may be also a thin rim of calcification in the pos-
terior border of the tumour. Angiography reveals a blood
supply from branches of the external carotid artery 
(ECA), usually the ascending pharyngeal and occipital
arteries [11].
At surgery, ELSTs are seen as reddish, firm lesions
with a nodular or polypoid surface. They are highly vas-
cularized and haemorrhagic [11,17,27]. The tumours also
may be dense and fibrous, and can adhere to vascular
structures and cranial nerves. Erosion of adjacent tem-
poral bone and dura mater is common. In advanced cas-
es, cerebellar tissue and/or cranial nerves could be infil-
trated. Location of tumour origin determines tumour
extension: if the neoplasm arises in the pars rugosa, it
extends into the petrous bone; if the tumour arises in
the intradural part of the endolymphatic sac, it extends
into the cerebellopontine angle and the jugular foramen.
Large tumours show a combined extension [31].
Histologically, ELST is adenocarcinoma of variable
cellularity that can invade and erode bone and soft tis-
sues. It is characterized by highly vascularized, poorly
circumscribed proliferation of cuboidal epithelial cells
forming a papillotubular pattern and occasional colloid-
filled cysts. These formations are lined by a single row
of cuboidal to low columnar or more flattened epithe-
lial cells with eosinophilic or vacuolated cytoplasm
[16,20]. The proportions of clear cells, follicle-like struc-
tures and of tumour stroma is variable [15,18,31]. Side -
rophages, siderosis of tumour cells and cholesterol clefts
are frequently found [6,15,32]. A capillary network imme-
diately subjacent to the epithelium corresponds to find-
ings in normal endolymphatic sac [15]. PAS-positivity
of tumour cells is typical and cytokeratin- and EMA-
immunoreactivity are regularly found [15,18,31]. Vimen -
tin-positivity of the basal portions of cytoplasm has 
previously been reported [13]. Immunohistochemical
detection of GFAP, NSE, synaptophysin and S-100 pro-
tein may show focal positivity [4,15,18,31-33]. Mitotic
figures are rarely present, necrosis is absent, and pleo-
morphism is minimal. From the point of view of diag-
nostic pathology, ELST located in the cerebellopontine
angle may be misleading towards diagnosis of a me -
tastatic adenocarcinoma. It is especially the case, when
the part of extensive destruction of petrous bone is
unknown for the pathologist (i.e. it is not reported).
In differential diagnosis of ELST the most attention
should be given to the folliculopapillary metastatic 
adenocarcinomas with similar morphologic features,
especially from thyroid, prostate, kidney and lung, but
this is unlikely in the absence of clinical knowledge of
the primary disease. Moreover, considering the male
gender of the patient and the profile of cytokeratins
(CK7+/CK20-) theoretically only metastatic lung car-
cinoma could be taken into account. However it must
emphasized that the tumour did not show any traces
of necroses in any form of inflammatory-reactive pro -
cess, which is typical of metastasis. Moreover, from the
morphological point of view, the local neoplastic pro -
cesses (like paraganglioma and choroid plexus papil-
loma) could be considered, but the first one does not
express cytokeratins and the second is quite unlikely
to be found inside the temporal bone.
Complete surgical resection of the endolymphat-
ic-sac tumours is curative and reported as the best
treatment for this neoplasm [2,35]. Morbidity is
thought to be related to the tumour size, however, 
5-year survival rates are not yet available. At early stages
it can be performed with the preservation of hearing
and the alleviation of vestibular symptoms. Deaf pa -
tients with evidence of a tumour on imaging should
undergo resection if other neurologic symptoms are
present [19].
The importance of adjunctive radiation remains
unclear [26], but inoperable tumours have been ra diated
[5]. Radiological follow-up with yearly MRI is indicat-
ed because of the aggressiveness and the proclivity for
bony invasion of these neoplasms [19]. The stereo-tac-
tically focussed radiotherapy (gamma-knife radiation)
was also used to treat residual and recurrent ELST
[3,7,11].
Conclusions
We have described a rare case of endolymphatic
sac tumour which presented most of typical clinical,
radiological and morphological features, with a history
longer than 6 years. The patient did not show any evi-
dence of VHL syndrome and his family histories were
negative. The course of the disease confirms a relatively
low aggressiveness of ELST. Until now, there has been
no wide agreement concerning diagnosis and thera-
py. The tumour natural history and the role of various
therapies will hopefully become available as the num-
 ber of reports of ELST increases.
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